Medication Pearl of the Day: Ofatumumab (Kesimpta)
Indication: Ofatumumab(Kesimpta) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- Dosing: Initial dosing: 20 mg administered at weeks 0, 1, and 2
- Dosage forms: Injection 20 mg/0.4 mL solution in a single-dose prefilled Sensoready Pen Injection: 20 mg/0.4 mL solution in a single-dose prefilled syringe
- Adverse events: Most common adverse reactions (incidence greater than 10%) are upper respiratory tract infection, headache, injection-related reactions, and local injection site reactions.
- Mechanism of action: The precise mechanism by which ofatumumab exerts its therapeutic effects in MS is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ofatumumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.
Source: kesimpta.pdf (novartis.us)